Pancreatic Ductal Adenocarcinoma malady

MalaCards: Pancreatic Ductal Adenocarcinoma, also known as ductal adenocarcinoma of the pancreas, is related to mucinous cystadenocarcinoma and breast carcinoma in situ. An important gene associated with Pancreatic Ductal Adenocarcinoma is S100PBP (S100P binding protein), and among its related pathways are Signal transduction AKT signaling and Pancreatic cancer. The compounds ceramide and gnrh have been mentioned in the context of this disorder. Affiliated tissues include whole blood, lymph node and pancreas, and related mouse phenotypes are respiratory system and endocrine/exocrine gland.

Aliases & Descriptions:

pancreatic ductal adenocarcinoma 6 8 43 ductal adenocarcinoma of the pancreas 6

ductal breast carcinoma 43

Diseases related to pancreatic ductal adenocarcinoma by text searches and GeneDecks gene sharing:

(show top 50)    (show all 806)

id	Related Disease	Score	Top Affiliating Genes
1	mucinous cystadenocarcinoma	32.6	MUC1, CEACAM3, SMAD4, TFF1
2	breast carcinoma in situ	32.4	VEGFC, CDH1, MET, ERBB2, TP53, KRT19
3	pancreatitis	32.3	PIM1, SH3GLB1, REG3A, REG4, SFN, SERPINB5
4	adenocarcinoma	32.2	PIM1, SH3GLB1, REG3A, REG4, SFN, SERPINB5
5	pancreatic cancer	31.7	SERPINB5, VEGFA, RAC1, BIRC5, CHGA, MUC1
6	adenosquamous carcinoma	31.3	CHGA, MUC1, MUC2, MUC5AC, CEACAM5, GRP
7	cribriform carcinoma	30.5	CDH1, ERBB2, TP53, SMAD4, PLAU, KRT8
8	cystadenocarcinoma	30.2	VIM, VEGFA, BIRC5, BCL2, MUC1, MUC2
9	cystadenoma	29.2	REG3A, REG4, VIM, BRAF, VEGFA, VEGFC
10	breast carcinoma	27.5	SFN, SERPINB5, SERPINH1, SERPINB2, VIM, BRAF
11	breast cancer	27.0	VEGFA, BCL2, MMP9, MLH1, FASN, CCND1
12	ductal carcinoma in situ	24.5	VIM, VEGFA, BIRC5, BCL2, BCL2L1, CHGA
13	wilms tumor	24.1	VIM, VEGFA, VEGFC, MYC, BMP6, BIRC5
14	carcinoma	22.6	PIM1, SH3GLB1, REG3A, REG4, SFN, SERPINB5
15	insulin resistance	22.1	VEGFA, VCAM1, BMP6, RAC1, BDNF, CHGA
16	hypoxia	21.0	PIM1, SERPINB5, BRAF, VEGFA, VEGFC, VCAM1
17	fibrosis	18.6	REG3A, SERPINH1, VIM, VEGFA, VEGFC, VCAM1
18	hepatitis	18.3	PIM1, SERPINH1, VIM, BRAF, VEGFA, VEGFC
19	hereditary pancreatitis	14.2	REG3A, SERPINB5, MUC2, MUC5AC, S100A4, S100A6
20	pancreatic ductal carcinoma	14.1	CHGA, MUC2, MUC5AC, GRP, FASLG, SMAD4
21	peutz-jeghers syndrome	14.0	MUC2, MUC5AC, SMAD4, TFF1
22	pseudomyxoma peritonei	14.0	REG4, VIM, MUC2, MUC5AC, CEACAM5, CDX2
23	bronchiolo-alveolar adenocarcinoma	14.0	MUC2, MUC5AC, CEACAM5, JUP, CDX2, CDH1
24	estrogen resistance	13.9	CCND1, HRAS, AKT1, AKT2, CYP1B1, TFF1
25	signet ring basal cell carcinoma	13.9	CHGA, MUC2, CEACAM5, CDH1
26	microinvasive gastric cancer	13.9	VEGFC, MUC2, CEACAM5, JUP, CDX2, CDH1
27	biliary papillomatosis	13.9	MUC1, MUC17, MUC2, MUC5AC
28	endocarditis	13.9	SERPINH1, VCAM1, VCP, LGALS1, FSCN1, CD40LG
29	vipoma	13.9	CHGA, MEN1, SST, NTS, SMAD4
30	acinar cell carcinoma	13.9	CHGA, CEACAM5, APC, CTNNB1, SMAD4
31	ampulla of vater adenocarcinoma	13.8	MUC1, MUC2, MUC5AC, CDX2
32	neurilemmoma	13.8	VIM, RAC1, MUC1, ITGA6, ENO2, EZR
33	skin carcinoma	13.8	CHGA, LAMC2, JUP, CDH1, TP53, KRT8
34	myelodysplastic syndrome	13.8	BMI1, BIRC5, FASLG, FAS, ANXA5, TNFRSF10A
35	ovarian cancer	13.8	CDKN1A, CDKN2A, CDC25B, CCNA2, CCND3, CCND1
36	autoimmune lymphoproliferative syndrome	13.8	FASLG, FAS, HRAS, TNFSF10, SPP1, KRAS
37	oxyphilic adenoma	13.8	VIM, MUC1, CA9, CAV1, KRT8, KRT19
38	mutyh-associated polyposis	13.7	APC, TP53, SMAD4, KRAS
39	dry eye syndrome	13.7	BDNF, LGALS1, MUC1, MUC5AC, NTF3, NGF
40	anaplastic carcinoma	13.7	VIM, BRAF, LGALS1, MUC1, S100A4, S100A6
41	atrophic gastritis	13.7	CHGA, CDX2, MEN1, MET, SST, TFF1
42	bile duct adenoma	13.7	MSLN, ERBB2, TP53, SMAD4, KRT19
43	neuroendocrine carcinoma	13.7	CHGA, MUC1, CEACAM5, FSCN1, CDX2, CDH1
44	breast fibroadenoma	13.7	VEGFC, MKI67, HMGA1, HMGA2, ERBB2, KRT8
45	follicular dendritic cell sarcoma	13.7	VIM, FSCN1, TP53, SNCG, SLC2A1
46	malignant pleural mesothelioma	13.7	BIRC5, BCL2L1, MUC1, CEACAM5, CEACAM3, MSLN
47	small intestine adenocarcinoma	13.7	BRAF, MUC1, MUC2, MUC5AC, BAX, CDX2
48	merkel cell carcinoma	13.7	CHGA, MUC1, ENO2, SST, KRT8, TOP2A
49	rectum cancer	13.7	BAX, CEACAM5, CEACAM3, HBEGF
50	ganglioneuroma	13.7	CHGA, ENO2, HMGA1, SST, NTF3, NTRK1

Approved drugs:

Drug clinical trials:

MalaCards organs/tissues related to pancreatic ductal adenocarcinoma:

²²

id	Organ / Tissue -> Anatomical Compartment -> Cell	Relevance
1	Pancreas -> Pancreatic Ducts	Affected by disease

MGI Mouse Phenotypes related to pancreatic ductal adenocarcinoma:

²⁵ (show all 29)

id	Description	MGI Source Accession	Score	Top Affiliating Genes
1	respiratory system phenotype	MP:0005388	10.8	BMPR1A, BDNF, CHRNA7, GYS1, AKAP12, NTF3
2	endocrine/exocrine gland phenotype	MP:0005379	10.7	SFN, BMPR1A, BHLHA15, YAP1, CD40LG, CDX2
3	craniofacial phenotype	MP:0005382	10.7	LMO4, BMI1, BMPR1A, BDNF, L1CAM, INHBA
4	immune system phenotype	MP:0005387	10.6	SFN, SERPINB2, VIM, BRAF, BMI1, BMPR1A
5	hematopoietic system phenotype	MP:0005397	10.4	PIM1, SFN, SERPINB2, BRAF, LMO4, BMI1
6	liver/biliary system phenotype	MP:0005370	9.5	SFN, VEGFA, BHLHA15, YAP1, CD36, MEN1
7	renal/urinary system phenotype	MP:0005367	9.4	BRAF, BHLHE40, BCL2, CHGA, CHUK, BAK1
8	other phenotype	MP:0005395	9.2	SERPINH1, LAMC2, CDKN2A, CD40LG, ITGA6, IL13
9	normal phenotype	MP:0002873	9.0	BRAF, VEGFA, MYC, BMPR1A, LIMS1, BDNF
10	limbs/digits/tail phenotype	MP:0005371	8.8	SFN, VEGFA, LMO4, BMI1, BMPR1A, RAC1
11	embryogenesis phenotype	MP:0005380	8.7	SFN, SERPINB5, VIM, BRAF, LMO4, MYC
12	pigmentation phenotype	MP:0001186	8.3	BRAF, MYC, BMPR1A, RAC1, BCL2, L1CAM
13	nervous system phenotype	MP:0003631	7.9	SERPINH1, BRAF, VCP, LMO4, MYC, BMI1
14	reproductive system phenotype	MP:0005389	7.8	SFN, VEGFA, BMPR1A, BECN1, CHUK, L1CAM
15	hearing/vestibular/ear phenotype	MP:0005377	7.5	SFN, LMO4, MYC, BMPR1A, BDNF, BCL2
16	mortality/aging	MP:0010768	7.4	SFN, SERPINB5, SERPINH1, SERPINB2, BRAF, VEGFA
17	behavior/neurological phenotype	MP:0005386	7.3	VIM, BRAF, VCP, LMO4, BMI1, BMPR1A
18	no phenotypic analysis	MP:0003012	7.3	VEGFA, VCAM1, MYC, BHLHE40, BDNF, MUC1
19	integument phenotype	MP:0010771	7.0	SFN, BRAF, LMO4, MYC, RAC1, BECN1
20	digestive/alimentary phenotype	MP:0005381	6.4	SFN, BRAF, VEGFA, MYC, BMI1, BHLHA15
21	growth/size phenotype	MP:0005378	5.9	PIM1, SFN, SERPINB2, BRAF, VCAM1, LMO4
22	adipose tissue phenotype	MP:0005375	5.7	BRAF, MYC, BCL2, CDKN1A, CD36, APC
23	skeleton phenotype	MP:0005390	5.0	SFN, BRAF, VEGFA, VCP, LMO4, MYC
24	tumorigenesis	MP:0002006	4.6	SFN, BRAF, MYC, BMI1, BMPR1A, BHLHA15
25	muscle phenotype	MP:0005369	4.2	SERPINB2, VIM, BRAF, VEGFA, VCP, MYC
26	vision/eye phenotype	MP:0005391	3.9	SFN, VIM, BRAF, VEGFA, LMO4, BMI1
27	cardiovascular system phenotype	MP:0005385	2.7	VIM, BRAF, VEGFA, VEGFC, VCAM1, MYC
28	cellular phenotype	MP:0005384	2.7	PIM1, SH3GLB1, SFN, SERPINB5, VIM, BRAF
29	homeostasis/metabolism phenotype	MP:0005376	2.2	REG3A, SERPINB2, VIM, BRAF, VEGFA, VEGFC

Articles related to pancreatic ductal adenocarcinoma:

(show top 50)    (show all 175)

id	Title	Authors	Year	Affiliating Genes
1	Overexpression of receptor tyrosine kinase Axl promot es tumor cell invasion and survival in pancreatic ductal adenocarcinoma. (20922806)	Song X.... Wang H.	2011	AXL, GAS6
2	Tumour epithelial vimentin expression and outcome of pancreatic ductal adenocarcinomas. (21448168)	Handra-Luca A.... Goggins M.	2011	VIM
3	Clinicopathologic correlation of beclin-1 expression in pancreatic ductal adenocarcinoma. (21420796)	Kim H.S.... Kim Y.W.	2011	BECN1
4	Galectin-1 secreted by activated stellate cells in pa ncreatic ductal adenocarcinoma stroma promotes proliferation and invasion of pa ncreatic cancer cells: an in vitro study on the microenvironment of pancreatic ductal adenocarcinoma. (21747316)	Xue X.... Jiang K.	2011	LGALS1
5	Elevated L1CAM expression in precursor lesions and pr imary and metastastic tissues of pancreatic ductal adenocarcinoma. (20811670)	Bergmann F.... Sebens MA1erkAPster S.	2010	L1CAM
6	The miR-217 microRNA functions as a potential tumor s uppressor in pancreatic ductal adenocarcinoma by targeting KRAS. (20675343)	Zhao W.G.... Chen J.	2010	KRAS, MIR217
7	Implications of enhancer of zeste homologue 2 express ion in pancreatic ductal adenocarcinoma. (20573371)	Toll A.D.... Witkiewicz A.K.	2010	CDH1, EZH2
8	Expression of Ezrin and phosphorylated Ezrin (pEzrin) in pancreatic ductal adenocarcinoma. (20158339)	Cui Y.... Han J.	2010	EZR
9	Clinical significance of ephrin (eph)-A1, -A2, -a4, - a5 and -a7 receptors in pancreatic ductal adenocarcinoma. (19949912)	Giaginis C.... Theocharis S.E.	2010	EPHA2, EPHA7, EPHA4
10	Differential roles of cyclin D1 and D3 in pancreatic ductal adenocarcinoma. (20113529)	Radulovich N.... Tsao M.S.	2010	CCND1, CCND3
11	Interleukin 13 mediates signal transduction through i nterleukin 13 receptor alpha2 in pancreatic ductal adenocarcinoma: role of IL-1 3 Pseudomonas exotoxin in pancreatic cancer therapy. (20068108)	Shimamura T.... Puri R.K.	2010	JUN, IL13, IL13RA2
12	The expression and significance of nerve growth fact or and its receptors in pancreatic ductal adenocarcinoma (19957796)	Meng L.X.... Hao X.S.	2009	NTRK1, NGF
13	Expression of a prometastatic splice variant of osteo pontin, OPNC, in human pancreatic ductal adenocarcinoma. (19628079)	Sullivan J.... Arafat H.A.	2009	SPP1
14	Caveolin-1 overexpression correlates with tumour progression markers in pancreatic ductal adenocarcinoma. (19160064)	Tanase C.P.... Hinescu M.E.	2009	TP53, CAV1, MKI67
15	Involvement of CD40 targeting miR-224 and miR-486 on the progression of pancreatic ductal adenocarcinomas. (19475450)	Mees S.T.... Haier J.	2009	CD40, MIR224, MIR486
16	Desmoplasia of pancreatic ductal adenocarcinoma. (19896098)	Pandol S.... Gukovskaya A.	2009	WNT2
17	In pancreatic ductal adenocarcinoma blood concentrati ons of some organochlorine compounds and coffee intake are independently associ ated with KRAS mutations. (19797353)	Porta M.... Real F.X.	2009	KRAS
18	High TRAIL death receptor 4 and decoy receptor 2 expression correlates with significant cell death in pancreatic ductal adenocarcinoma patients. (18981952)	Sanlioglu A.D.... Sanlioglu S.	2009	TNFSF10, TNFRSF10A, TNFRSF10D
19	Decreased expression of Angiotensin-converting enzyme 2 in pancreatic ductal adenocarcinoma is associated with tumor progression. (19212105)	Zhou L.... Yuan Y.	2009	ACE2
20	Induction of osteopontin expression by nicotine and c igarette smoke in the pancreas and pancreatic ductal adenocarcinoma cells. (19358273)	Chipitsyna G.... Arafat H.A.	2009	SPP1
21	Adenovirus-mediated eukaryotic initiation factor 4E binding protein-1 in combination with rapamycin inhibits tumor growth of pancreatic ductal adenocarcinoma in vivo. (19360336)	Mishra R.... Kondo S.	2009	EIF4E, EIF4EBP1
22	Co-expression of KLK6 and KLK10 as prognostic factors for survival in pancreatic ductal adenocarcinoma. (18854834)	Ruckert F.... Grutzmann R.	2008	KLK10, KLK6
23	The chemokine receptor CX3CR1 is involved in the neural tropism and malignant behavior of pancreatic ductal adenocarcinoma. (18974152)	Marchesi F.... Allavena P.	2008	CX3CR1
24	Proteomic analysis to identify biomarker proteins in pancreatic ductal adenocarcinoma. (18366394)	Chung J.C.... Bae C.D.	2008	ENO2, LGALS1, PRDX4
25	Prognostic significance of growth factors and the urokinase-type plasminogen activator system in pancreatic ductal adenocarcinoma. (18376307)	Xue A.... Smith R.C.	2008	PLAU, SERPINB2
26	Podocalyxin-like protein 1 expression is useful to differentiate pancreatic ductal adenocarcinomas from adenocarcinomas of the biliary and gastrointestinal tracts. (17137615)	Ney J.T.... Gutgemann I.	2007	PODXL
27	Simultaneous deregulation of p16 and cyclin D1 genes in pancreatic ductal adenocarcinoma: a combined immunohistochemistry and image analysis study based on tissue microarrays. (17600882)	Tsiambas E.... Patsouris E.	2007	CCND1, CDKN2A
28	Phosphoinositide-3-kinase signaling controls S-phase kinase-associated protein 2 transcription via E2F1 in pancreatic ductal adenocarcinoma cells. (17483325)	Reichert M.... Schneider G.	2007	AKT1, E2F1, SKP2
29	Antihypertensives as novel antineoplastics: angiotensin-I-converting enzyme inhibitors and angiotensin II type 1 receptor blockers in pancreatic ductal adenocarcinoma. (17481528)	Arafat H.A.... Yeo C.J.	2007	ACE, VEGFA, AGTR1
30	Dissociation of gemcitabine sensitivity and protein kinase B signaling in pancreatic ductal adenocarcinoma models. (17895832)	Pham N.A.... Hedley D.W.	2007	AKT2, AKT1, AKT3
31	Survivin expression in pancreatic intraepithelial neoplasia (PanIN): steady increase along the developmental stages of pancreatic ductal adenocarcinoma. (16723855)	Bhanot U.... Hasel C.	2006	BIRC5
32	TRAIL promotes metastasis of human pancreatic ductal adenocarcinoma. (16751802)	Trauzold A.... Wajant H.	2006	PLAU, TNFSF10
33	Yes-associated protein (YAP65) in relation to Smad7 expression in human pancreatic ductal adenocarcinoma. (16596258)	Guo J.... Friess H.	2006	SMAD4, SMAD7, YAP1
34	GADD45alpha is highly expressed in pancreatic ductal adenocarcinoma cells and required for tumor cell viability. (16353139)	Schneider G.... Liptay S.	2006	CHUK, GADD45A
35	Aberrant methylation of Reprimo correlates with genetic instability and predicts poor prognosis in pancreatic ductal adenocarcinoma. (16752411)	Sato N.... Goggins M.	2006	TP53, RPRM
36	Distribution of somatostatin in pancreatic ductal adenocarcinoma remodels the normal pattern of the protein during foetal pancreatic development: an immunohistochemical analysis. (16284732)	Tamiolakis D.... Papadopoulos N.	2005	SST
37	Aberrant expression of cdx2 homeobox gene in intraductal papillary-mucinous neoplasm of the pancreas but not in pancreatic ductal adenocarcinoma. (15782100)	Yeh T.S.... Chen M.F.	2005	MUC2, CDX2, MUC5AC
38	Expression of hypoxia-inducible factors is correlated with the presence of a fibrotic focus and angiogenesis in pancreatic ductal adenocarcinomas. (15910598)	Couvelard A.... Pezzella F.	2005	CA9
39	Expression and functional significance of CDC25B in human pancreatic ductal adenocarcinoma. (14712212)	Guo J.... Friess H.	2004	CDC25B
40	Frequent hypomethylation of multiple genes overexpressed in pancreatic ductal adenocarcinoma. (12874021)	Sato N.... Goggins M.	2003	S100A4, MSLN
41	Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies. (14695172)	Iacobuzio-Donahue C.A.... Hruban R.H.	2003	SFN
42	Lack of apoptosis in PanIN-1 and PanIN-2 lesions associated with pancreatic ductal adenocarcinoma is not dependent on K-ras status. (14508142)	Luttges J.... Kloppel G.	2003	KRAS
43	Aberrant methylation of the 5' CpG island of TSLC1 is common in pancreatic ductal adenocarcinoma and is first manifest in high-grade PanlNs. (12432281)	Jansen M.... Goggins M.	2002	CADM1
44	Detailed tissue expression of bcl-2, bax, bak and bcl-x in the normal human pancreas and in chronic pancreatitis, ampullary and pancreatic ductal adenocarcinomas. (12120204)	Evans J.D.... Neoptolemos J.P.	2001	TP53, BCL2, BCL2L1
45	The SMAD4 protein and prognosis of pancreatic ductal adenocarcinoma. (11751510)	Tascilar M.... Goggins M.	2001	SMAD4
46	Tyrosine nitration of c-SRC tyrosine kinase in human pancreatic ductal adenocarcinoma. (10845713)	MacMillan-Crow L.A.... Thompson J.A.	2000	CSK
47	Neurotrophins and Trk receptors in human pancreatic ductal adenocarcinoma: expression patterns and effects on in vitro invasive behavior. (10209957)	Miknyoczki S.J.... Ruggeri B.A.	1999	BDNF, NTF3, NTS
48	The intracellular mechanism of insulin resistance in the hamster pancreatic ductal adenocarcinoma model. (9821177)	Liu J.... Adrian T.E.	1998	PYGM, GYS1
49	Ki-ras and p53 mutations in pancreatic ductal adenocarcinoma. (8927612)	Rall C.J.... Rustgi A.K.	1996	TP53
50	Bombesin inhibits growth of pancreatic ductal adenocarcinoma (H2T) in nude mice. (7809021)	Farre A.... Thompson J.C.	1994	MT3, GRP

Genes related to pancreatic ductal adenocarcinoma according to GeneCards:

(show top 50)    (show all 229)

id	Symbol	Description	Score	GeneCards Section Context
1	S100PBP	S100P binding protein	11.1	Summaries, Expressions
2	MIR486	microRNA 486	11.0	Publications
3	MIR217	microRNA 217	11.0	Publications
4	MIR224	microRNA 224	11.0	Publications
5	MIR196A1	microRNA 196a-1	11.0	Publications
6	RPRM	reprimo, TP53 dependent G2 arrest mediator candidate	11.0	Publications
7	ZG16B	zymogen granule protein 16 homolog B (rat)	11.0	Publications
8	BHLHA15	basic helix-loop-helix family, member a15	11.0
9	DYRK1B	dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1B	11.0	Publications
10	IMP3	IMP3, U3 small nucleolar ribonucleoprotein, homolog (yeast)	11.0	Publications
11	A1BG	alpha-1-B glycoprotein	11.0	Publications
12	AKR7A2	aldo-keto reductase family 7, member A2 (aflatoxin aldehyde reductase)	11.0	Publications
13	S100P	S100 calcium binding protein P	11.0	Expressions
14	GPC1	glypican 1	11.0	Publications
15	FXYD3	FXYD domain containing ion transport regulator 3	11.0	Publications
16	HOXC8	homeobox C8	11.0	Publications
17	SNCG	synuclein, gamma (breast cancer-specific protein 1)	11.0	Publications
18	BHLHE40	basic helix-loop-helix family, member e40	11.0	Publications
19	REG4	regenerating islet-derived family, member 4	11.0	Publications
20	NGRN	neugrin, neurite outgrowth associated	11.0	Publications
21	CD24	CD24 molecule	11.0	Publications
22	SAGE1	sarcoma antigen 1	11.0	Publications
23	MT3	metallothionein 3	11.0	Publications
24	KLK10	kallikrein-related peptidase 10	11.0	Publications
25	REG3A	regenerating islet-derived 3 alpha	11.0	Publications
26	LMO4	LIM domain only 4	11.0	Publications
27	AGR2	anterior gradient 2 homolog (Xenopus laevis)	11.0	Publications
28	FXYD5	FXYD domain containing ion transport regulator 5	11.0	Publications
29	C2orf18	chromosome 2 open reading frame 18	11.0
30	PSCA	prostate stem cell antigen	11.0	Publications
31	CTSE	cathepsin E	11.0	Publications
32	PENK	proenkephalin	11.0	Publications
33	EBAG9	estrogen receptor binding site associated, antigen, 9	11.0	Publications
34	CXCR6	chemokine (C-X-C motif) receptor 6	11.0	Publications
35	CXCL16	chemokine (C-X-C motif) ligand 16	11.0	Publications
36	KLK6	kallikrein-related peptidase 6	11.0	Publications
37	TFPI2	tissue factor pathway inhibitor 2	11.0	Publications
38	TDG	thymine-DNA glycosylase	11.0	Publications
39	MIR21	microRNA 21	11.0	Publications
40	MSLN	mesothelin	11.0	Publications
41	SFN	stratifin	11.0	Publications
42	SERPINB5	serpin peptidase inhibitor, clade B (ovalbumin), member 5	11.0	Publications
43	RGL3	ral guanine nucleotide dissociation stimulator-like 3	11.0	Disorders
44	GAS6	growth arrest-specific 6	11.0	Publications
45	GDF15	growth differentiation factor 15	11.0	Publications
46	GYS1	glycogen synthase 1 (muscle)	11.0	Publications
47	LAMC2	laminin, gamma 2	11.0	Publications
48	POSTN	periostin, osteoblast specific factor	11.0	Publications
49	INHBA	inhibin, beta A	11.0	Publications
50	IL13RA2	interleukin 13 receptor, alpha 2	11.0	Publications

Pathways related to pancreatic ductal adenocarcinoma according to GeneDecks:

(show top 50)    (show all 350)

id	Pathway	Score	Top Affiliating Genes
1	Signal transduction AKT signaling10	11.0	GYS1
2	Pancreatic cancer20	10.9	AKT2, AKT3
3	Apoptosis and survival Role of CDK5 in neuronal death and survival10	10.3	BCL2, AKT3, ERBB3, NTRK1, NGF
4	Colorectal cancer20	10.3	BRAF, RAC1, AKT3, SMAD2, SMAD3, RHOA
5	Akt Signaling36	9.9	VEGFC, BMPR1A, CHUK, YAP1, AXL, ITGA6
6	Non-small cell lung cancer20	9.9	BRAF, CDKN2A, HRAS, AKT1, AKT2, AKT3
7	Breast Cancer Regulation by Stathmin136	9.7	RAC1, AXL, FGF2, IGF1R, ERBB3, ERBB2
8	Glioblastoma Multiforme36	9.5	BRAF, RAC1, CDKN1A, APC, MAPK3, IGF1R
9	Development_Neurotrophin family signaling41	9.3	BRAF, RAC1, BDNF, BAX, JUN, MAPK3
10	Paxillin Interactions36	9.3	VEGFC, RAC1, BDNF, AXL, ITGA3, ITGA6
11	Signal transduction_AKT signaling41	9.3	MYC, BCL2L1, CHUK, BAX, CDKN1A, GYS1
12	mTOR Pathway36	9.2	VEGFC, BMP6, RAC1, BDNF, AXL, FGF2
13	Epithelial Adherens Junctions36	9.0	VEGFC, BMP6, RAC1, BDNF, CHUK, JUP
14	Endothelin-1 Signaling Pathway36	9.0	BRAF, MYC, BMP6, AXL, IL13, MAPK3
15	14-3-3 Induced Intracellular Signaling36	9.0	VEGFC, BDNF, YAP1, AXL, JUN, FGF2
16	PTEN Pathway36	8.9	BRAF, VEGFC, RAC1, BDNF, LAMC2, ITGA3
17	Chronic myeloid leukemia20	8.9	BRAF, MYC, BCL2L1, CHUK, CDKN1A, CDKN2A
18	PPAR Pathway36	8.9	VEGFC, ITGA3, ITGA6, FGF2, MET, IGF1R
19	Melanoma20	8.8	BRAF, CDKN1A, CDKN2A, CDH1, FGF2, MET
20	Activation of PKA through GPCR36	8.8	BRAF, VEGFC, BMP6, BDNF, CHUK, AXL
21	Small cell lung cancer20	8.7	MYC, BCL2, BCL2L1, CHUK, LAMC2, ITGA3
22	JNK Pathway36	8.6	BMP6, RAC1, BCL2, BAX, AXL, JUN
23	Endometrial cancer20	8.5	BRAF, MYC, CDH1, MLH1, APC, MAPK3
24	STAT3 Pathway36	8.4	PIM1, BRAF, MYC, BMP6, BMPR1A, RAC1
25	p53 Mediated Apoptosis36	8.4	VEGFC, BMP6, BDNF, BCL2, BAX, FGF2
26	Cellular Apoptosis Pathway36	8.4	VEGFC, BMP6, BDNF, BCL2, BCL2L1, CHUK
27	Mitochondrial Apoptosis36	8.4	VEGFC, BMP6, BDNF, BCL2, BCL2L1, BAK1
28	Ras Pathway36	8.3	BRAF, VEGFC, AXL, JUN, ITGA3, ITGA6
29	ERK Signaling36	8.2	BRAF, VEGFC, MYC, BMP6, CHUK, LAMC2
30	p38 Signaling36	8.1	VEGFC, BMP6, BMPR1A, RAC1, BDNF, BCL2
31	Development_EGFR signaling pathway41	8.0	MYC, RAC1, CHUK, JUN, MMP9, MAPK3
32	Nanog in Mammalian ESC Pluripotency36	8.0	BRAF, VEGFC, BMP6, BDNF, AXL, FGF2
33	ErbB signaling pathway20	8.0	BRAF, MYC, JUN, CDKN1A, MAPK3, HRAS
34	Focal adhesion20	7.9	BRAF, VEGFC, RAC1, BCL2, LAMC2, JUN
35	P2Y Receptor Signaling36	7.9	BRAF, VEGFC, MYC, AXL, JUN, FGF2
36	Rho Family GTPases36	7.9	VIM, VEGFC, BMP6, RAC1, BDNF, BCL2
37	Antioxidant Action of Vitamin-C36	7.8	VEGFC, BMP6, BMPR1A, RAC1, BDNF, BCL2
38	ILK Signaling36	7.8	VIM, VEGFC, RAC1, LIMS1, BDNF, LAMC2
39	GPCR Pathway36	7.7	BRAF, VEGFC, BMP6, RAC1, BDNF, CHUK
40	MAPK Family Pathway36	7.6	BRAF, VEGFC, BMP6, RAC1, BDNF, BCL2
41	MAPK signaling pathway20	7.5	BRAF, MYC, RAC1, BDNF, CHUK, JUN
42	Bladder cancer20	7.4	BRAF, VEGFA, VEGFC, MYC, CDKN1A, CDKN2A
43	Renin-Angiotensin Pathway36	7.3	VEGFC, VCAM1, BMP6, RAC1, BDNF, CHUK
44	Estrogen Pathway36	7.2	BRAF, VEGFC, BMP6, BDNF, BCL2, CHUK
45	Colorectal Cancer Metastasis36	7.0	BRAF, MYC, BIRC5, BCL2L1, BAX, CDKN1A
46	MAPK Signaling36	6.8	BRAF, VEGFC, MYC, BMP6, RAC1, BDNF
47	JAK-STAT Pathway36	6.6	VEGFC, MYC, BMP6, BDNF, BCL2, BAX
48	Molecular Mechanisms of Cancer36	6.2	VEGFC, MYC, BMP6, BMPR1A, BDNF, BCL2
49	Pancreatic Adenocarcinoma36	6.2	BRAF, VEGFC, BMP6, RAC1, BIRC5, BDNF
50	Pathways in cancer20	5.3	VEGFA, VEGFC, MYC, RAC1, BIRC5, BCL2

Compounds related to pancreatic ductal adenocarcinoma according to GeneDecks:

(show top 50)    (show all 400)

id	Compound	Score	Top Affiliating Genes
1	ceramide32	10.4	BECN1, BCL2L1, LGALS1, BAK1, FASN, ANXA5
2	gnrh32	9.8	VIM, MT3, MKI67, GRP, FASLG, AKT1
3	superoxide32 18	10.5	SFN, SERPINB2, VCAM1, VCP, RAC1, BIRC5
4	atp32	9.5	PIM1, SERPINH1, BRAF, VCP, RAC1, BIRC5
5	estradiol32 9 18 9	12.5	VIM, VEGFC, BIRC5, BDNF, MUC1, BAK1
6	lovastatin32 42 9 9	12.5	RAC1, CHRNA7, CDKN1A, CDKN2A, CD40, FASLG
7	nocodazole32 42 9 9	12.4	VIM, RAC1, BIRC5, BDNF, CDKN1A, CDH1
8	p00232	9.4	SERPINB5, BRAF, BIRC5, CHGA, CEACAM5, JUP
9	c2ceramide32	9.3	BECN1, BCL2L1, CHUK, BAX, JUN, AKT1
10	arginine32	9.2	BRAF, RAC1, LGALS1, CHGA, CD40LG, MLH1
11	oxaliplatin32 34 9 9	12.2	VEGFA, BIRC5, BCL2L1, CEACAM5, CDKN1A, MLH1
12	guanine32 9 18 9	12.1	RAC1, BIRC5, CHGA, L1CAM, MMP9, GRP
13	methotrexate32 34 42 9 9	13.1	VIM, BMP6, BIRC5, MUC1, MUC2, MUC5AC
14	epinephrine32 9 18 9	12.1	BMP6, BDNF, CHGA, MMP9, GYS1, GRP
15	glycogen32 18	10.1	VIM, MYC, CHGA, CHUK, CEACAM5, CD40
16	nitric oxide32 9 18 9	11.7	SERPINB5, SERPINH1, SERPINB2, VEGFC, VCAM1, BMP6
17	mifepristone32 42 9 9	11.6	BIRC5, BCL2L1, MUC1, BAX, JUN, MKI67
18	rottlerin32 42	9.6	VCAM1, RAC1, JUN, CD36, CD40LG, GRP
19	aspartate32	8.6	VIM, BRAF, BMP6, BDNF, CHRNA7, CEACAM3
20	lactate32	8.4	VIM, VCAM1, BMP6, BIRC5, BDNF, CHGA
21	n acetylcysteine32	8.3	VCAM1, BIRC5, BDNF, CHUK, MUC5AC, CDKN1A
22	cysteine32	8.3	RAC1, PARK7, BCL2L1, LGALS1, CHRNA7, CHUK
23	acetylcholine32 9 18 9	11.3	VIM, BMP6, RAC1, BDNF, CHRNA7, CHGA
24	12-o-tetradecanoylphorbol 13-acetate32	8.2	SERPINB2, BRAF, MYC, BMP6, CHUK, MUC2
25	irinotecan32 34 9 9	11.1	BRAF, VEGFA, BCL2L1, BAK1, BAX, CEACAM5
26	cytochalasin d32 42	9.1	VIM, VCAM1, RAC1, CD36, CDH1, MMP9
27	thymidylate32	8.1	VIM, VEGFA, BIRC5, BCL2, BCL2L1, BAX
28	creatinine32	8.0	VIM, BMP6, BDNF, CHGA, MUC1, MT3
29	agar32	7.8	VIM, BRAF, RAC1, BIRC5, LGALS1, MUC1
30	calcitriol32 42 9 18 9	11.8	MYC, BMP6, BAK1, JUN, CDKN1A, CD36
31	oxygen32 18	8.8	RAC1, BIRC5, BECN1, PARK7, BDNF, BCL2
32	mg 13232 42	8.7	MYC, BIRC5, BCL2L1, BAX, JUN, CDKN1A
33	sulindac32 9 9	9.7	BIRC5, BCL2, BCL2L1, BAX, CDKN1A, CDH1
34	glutamine32	7.5	VIM, VCP, BMP6, LGALS1, CD36, CDH1
35	lactacystin32	7.5	MYC, BIRC5, BCL2, BCL2L1, JUN, CDKN1A
36	geldanamycin32 9 9	9.5	PIM1, BRAF, VEGFA, BIRC5, BCL2L1, JUN
37	docetaxel32 34 9 9	10.3	VEGFA, MYC, BIRC5, BCL2, BCL2L1, BAK1
38	phosphoinositide32	7.1	VIM, BRAF, RAC1, BIRC5, BDNF, BCL2L1
39	retinoid32	7.0	VIM, MYC, BMP6, BCL2, BCL2L1, LGALS1
40	adriamycin32	6.7	VIM, MYC, BIRC5, BCL2, BCL2L1, MUC1
41	thymidine32 18	7.4	REG3A, VEGFC, MYC, BMP6, RAC1, BIRC5
42	arsenite32 18	7.2	VEGFA, MYC, RAC1, BIRC5, BECN1, BCL2
43	alanine32	6.1	PIM1, BRAF, VCAM1, MYC, BMP6, BIRC5
44	matrigel32	5.9	SERPINB5, SERPINB2, VIM, BRAF, VEGFA, VEGFC
45	testosterone32 9 18 9	8.8	SERPINB5, VIM, VEGFC, VCAM1, BIRC5, PARK7
46	phosphatidylinositol32	5.5	BRAF, VEGFC, VCAM1, MYC, BMP6, RAC1
47	paraffin32	5.4	SERPINB5, SERPINB2, VIM, BRAF, VEGFA, VEGFC
48	herbimycin a32 42	5.8	VCAM1, MYC, BMP6, JUN, CD36, CD40LG
49	pd 98,05932	3.8	BRAF, VEGFC, VCAM1, MYC, BMP6, RAC1
50	actinomycin d32	3.8	SERPINB2, VIM, VEGFA, MYC, BIRC5, BDNF

Cellular components related to pancreatic ductal adenocarcinoma according to GeneDecks:

(show all 21)

id	Name	GO ID	Score	Top Affiliating Genes
1	catenin complex	GO:016342	10.7	SMAD7, CTNNB1, CTNNA1, CDH1, JUP
2	SMAD protein complex	GO:071141	10.6	SMAD4, SMAD3, SMAD2, HMGA2
3	cell-cell adherens junction	GO:005913	10.4	SMAD7, CTNNB1, APC, ITGA6, CDH1, JUP
4	Golgi lumen	GO:005796	10.3	GAS6, TGFB1, NGF, GPC1, MUC5AC, MUC2
5	membrane raft	GO:045121	10.3	ADAM17, PODXL, TLR4, ACE2, EGFR, KRAS
6	basolateral plasma membrane	GO:016323	10.0	SLC2A1, ST14, EGFR, ERBB2, ERBB3, CAV1
7	transcription factor complex	GO:005667	9.9	SMAD7, SMAD4, SMAD3, SMAD2, CTNNB1, HMGA1
8	perinuclear region of cytoplasm	GO:048471	9.9	ERBB2, SPP1, CTNNB1, SNCG, NOS2, EGFR
9	cell surface	GO:009986	9.9	PDGFA, ACE2, HBEGF, TGFB1, PROM1, CXCR4
10	focal adhesion	GO:005925	9.8	EPHA2, ADAM17, EBAG9, PTK2, CAV1, EZR
11	caveola	GO:005901	9.7	SLC2A1, TGFBR2, SRC, PTGS2, CAV1, MAPK3
12	integral to plasma membrane	GO:005887	9.6	PROM1, ST14, TLR4, AGTR1, HBEGF, NRG1
13	extracellular region	GO:005576	9.2	KLK10, PDGFA, NGRN, NGF, PLAU, NRG1
14	external side of plasma membrane	GO:009897	9.1	ANXA5, ACE, TLR4, TGFBR2, CXCR4, EPHA5
15	protein complex	GO:043234	8.9	TOP2A, EIF4EBP1, SSBP3, PTGS2, TP53, CAV1
16	plasma membrane	GO:005886	8.1	RHOA, RHOB, RHOC, KRAS, EGF, EGFR
17	extracellular space	GO:005615	7.9	GDF15, EGFR, EGF, PDGFA, NGF, PLAU
18	nucleoplasm	GO:005654	7.7	SKP2, RXRA, SMAD7, SMAD4, SMAD3, SMAD2
19	cytosol	GO:005829	7.0	PPARG, CTNNB1, CTNNA1, SRC, PTK2, PYGM
20	cytoplasm	GO:005737	6.2	PTK2, SP1, CTNNB1, NRG1, SNAI2, SMAD2
21	nucleus	GO:005634	5.8	SSBP3, SRC, SP1, CTNNB1, PPARG, NRG1

Biological processes related to pancreatic ductal adenocarcinoma according to GeneDecks:

(show top 50)    (show all 107)

id	Name	GO ID	Score	Top Affiliating Genes
1	activation of MAPKK activity	GO:000186	10.8	NTRK1
2	cell adhesion	GO:007155	10.7	CD97, CD36, MSLN, L1CAM, LAMC2, RAC1
3	positive regulation of reactive oxygen species metabolic process	GO:2000379	10.2	CDKN1A, CD36, TP53, ACE2, AGTR1, TGFBR2
4	cell proliferation	GO:008283	10.2	FSCN1, MT3, YAP1, BAK1, BCL2L1, SFN
5	positive regulation of protein kinase B signaling cascade	GO:051897	10.1	HPSE, HBEGF, NRG1, EGFR, PDGFA, F3
6	positive regulation of cell migration	GO:030335	10.0	HBEGF, APC, VEGFA, EGFR, IGF1R, PDGFA
7	cellular response to mechanical stimulus	GO:071260	10.0	GADD45A, TLR4, TNFRSF10A, FAS, IL13, CD40
8	axon guidance	GO:007411	10.0	EZR, ACTG1, EPHA5, MET, CD24, RHOC
9	positive regulation of MAP kinase activity	GO:043406	9.9	EGFR, CD40, EGF, KRAS, PDGFA, ERBB2
10	positive regulation of cell growth	GO:030307	9.8	AKT1, ERBB2, NRG1, RHOC, HBEGF, CXCL16
11	cell cycle arrest	GO:007050	9.8	TP53, GADD45A, GAS6, RPRM, SMAD3, TGFB1
12	Ras protein signal transduction	GO:007265	9.8	CDKN2A, CCNA2, CDKN1A, HRAS, TP53, KRAS
13	positive regulation of fibroblast proliferation	GO:048146	9.7	S100A6, BMI1, MYC, JUN, CDKN1A, PDGFA
14	positive regulation of angiogenesis	GO:045766	9.7	HIF1A, RHOB, NTRK1, F3, MMP9, CHRNA7
15	epidermal growth factor receptor signaling pathway	GO:007173	9.7	CHUK, ADAM17, CSK, TGFB1, HBEGF, EGFR
16	virus-host interaction	GO:019048	9.6	KRT8, KRT19, EIF4E, CXCR4, CX3CR1, RXRA
17	positive regulation of protein phosphorylation	GO:001934	9.6	MT3, CD40, MAPK3, CCND3, HRAS, AKT1
18	aging	GO:007568	9.6	F3, PEBP1, TGFB1, TOP2A, RXRA, CTNNA1
19	MAPK cascade	GO:000165	9.4	HRAS, CAV1, MAPK3, MEN1, MYC, KRAS
20	negative regulation of neuron apoptotic process	GO:043524	9.4	BRAF, PARK7, BDNF, BCL2, BCL2L1, BAX
21	protein phosphorylation	GO:006468	9.4	GAS6, ERBB2, NTRK1, TGFB1, TGFBR2, CSK
22	induction of apoptosis by intracellular signals	GO:008629	9.4	BCL2, MYC, BCL2L1, BAK1, BAX, CDKN1A
23	transforming growth factor beta receptor signaling pathway	GO:007179	9.4	TGFB1, MYC, BMPR1A, JUN, MEN1, TP53
24	response to gamma radiation	GO:010332	9.3	BCL2, BAK1, BAX, MEN1, CAV1, TP53
25	activation of pro-apoptotic gene products	GO:008633	9.3	SMAD3, TNFSF10, AKT1, FAS, FASLG, BAX
26	positive regulation of peptidyl-serine phosphorylation	GO:033138	9.3	VEGFA, GAS6, AKT1, CAV1, MET, TGFB1
27	positive regulation of apoptotic process	GO:043065	9.3	MMP9, ITGA6, BAX, BAK1, MEN1, TLR4
28	response to estrogen stimulus	GO:043627	9.1	GATA4, BCL2, CD24, FAS, CCND1, CAV1
29	negative regulation of transcription from RNA polymerase II promoter	GO:000122	9.1	SMAD3, SMAD4, SMAD2, SNAI2, MYC, SMAD7
30	response to organic cyclic compound	GO:014070	9.1	PEBP1, BAK1, JUN, CDKN1A, MET, CCND1
31	release of cytochrome c from mitochondria	GO:001836	9.0	TP53, JUN, BAK1, BAX, BCL2L1, BCL2
32	positive regulation of epithelial cell proliferation	GO:050679	9.0	VEGFC, BMP6, TGFB1, EGFR, ERBB2, HRAS
33	negative regulation of cell proliferation	GO:008285	9.0	CTNNB1, TGFB1, INHBA, CSK, SFN, BECN1
34	inflammatory response	GO:006954	9.0	TGFB1, NGF, RXRA, CD97, SPP1, PTGS2
35	platelet activation	GO:030168	9.0	PTK2, TGFB1, SRC, PDGFA, RHOA, RHOB
36	response to DNA damage stimulus	GO:006974	8.8	YAP1, MAPK3, CCND1, TP53, TOP2A, CDKN1A
37	negative regulation of cell growth	GO:030308	8.8	CDKN1A, MT3, BCL2, SMAD4, CDKN2A, WT1
38	response to hypoxia	GO:001666	8.8	HIF1A, TLR4, TGFB1, CXCR4, SMAD4, RHOC
39	anti-apoptosis	GO:006916	8.8	BCL2L1, SH3GLB1, SERPINB2, BCL2, ADAM17, NGF
40	activation of cysteine-type endopeptidase activity involved in apoptotic process	GO:006919	8.7	TNFRSF10A, MYC, F3, TNFSF10, SMAD3, BAX
41	apoptotic process	GO:006915	8.7	BCL2L1, MAPK3, FAS, FASLG, APC, FGF2
42	blood coagulation	GO:007596	8.7	ITGA6, ITGA3, CD36, L1CAM, RAC1, VEGFC
43	positive regulation of cell proliferation	GO:008284	8.6	FGF2, NGF, EPHA1, PDGFA, KRAS, EGF
44	negative regulation of apoptotic process	GO:043066	8.5	APC, BRAF, PIM1, BCL2, MYC, VEGFA
45	response to lipopolysaccharide	GO:032496	8.5	F3, JUN, MMP9, IL13, FASLG, FAS
46	negative regulation of transcription, DNA-dependent	GO:045892	8.4	HMGA2, FGF2, CDKN2A, JUN, MT3, BIRC5
47	signal transduction	GO:007165	8.4	CCND3, ANXA5, FAS, FASLG, IL4R, IL13RA2
48	positive regulation of transcription, DNA-dependent	GO:045893	7.8	HMGA2, CDKN2A, CTNNB1, FGF2, WT1, EGF
49	positive regulation of transcription from RNA polymerase II promoter	GO:045944	7.3	VEGFA, LMO4, MYC, BMP6, INHBA, ITGA6
50	response to drug	GO:042493	6.4	PPARG, VEGFC, MYC, PARK7, BDNF, BCL2

Molecular functions related to pancreatic ductal adenocarcinoma according to GeneDecks:

(show all 21)

id	Name	GO ID	Score	Top Affiliating Genes
1	cadherin binding	GO:045296	10.6	PROM1, CTNNB1, CTNNA1, APC, JUP, FXYD5
2	protein phosphatase binding	GO:019903	10.2	CSK, EGFR, CTNNB1, ERBB2, CDH1, JUP
3	transmembrane receptor protein tyrosine kinase activity	GO:004714	10.2	EPHA2, EGFR, NTRK1, ERBB2, ERBB3, AXL
4	R-SMAD binding	GO:070412	10.1	SMAD4, SMAD3, SMAD2, CTNNB1, MEN1, JUN
5	protein tyrosine kinase activity	GO:004713	10.0	EPHA7, CSK, EGFR, SRC, DYRK1B, ERBB2
6	protein C-terminus binding	GO:008022	10.0	TOP2A, CTNNB1, SP1, ERBB2, HRAS, CADM1
7	protein tyrosine kinase activator activity	GO:030296	10.0	GAS6, NRG1, ERBB3, CD24
8	protein kinase binding	GO:019901	9.9	CCND1, TP53, PTK2, SMAD3, HIF1A, EPHA1
9	receptor binding	GO:005102	9.7	NRG1, NOS2, CXCL16, PGR, PEBP1, GAS6
10	chromatin binding	GO:003682	9.5	GATA4, TOP2A, RNF2, SMAD4, SMAD2, SNAI2
11	identical protein binding	GO:042802	9.5	IGF1R, AKT1, ERBB2, TP53, SMAD4, SKP2
12	cytokine activity	GO:005125	9.3	GDF15, WNT2, NRG1, SPP1, TNFSF10, FASLG
13	ATP binding	GO:005524	9.2	TTLL4, ACTG1, EGFR, PFKP, NTRK1, SRC
14	growth factor activity	GO:008083	9.2	PDGFA, EGF, HBEGF, TGFB1, TFF1, GDF15
15	double-stranded DNA binding	GO:003690	9.2	EGFR, WT1, RXRA, SMAD3, SMAD2, CTNNB1
16	transcription regulatory region DNA binding	GO:044212	9.1	SMAD4, SMAD7, RXRA, WT1, HIF1A, GATA4
17	transcription factor binding	GO:008134	8.7	SP1, CTNNB1, SMAD2, SMAD3, HIF1A, E2F1
18	protein homodimerization activity	GO:042803	8.7	SP1, PTGS2, ERBB3, CADM1, ENO2, CTSE
19	enzyme binding	GO:019899	8.4	PPARG, RXRA, EGFR, HIF1A, TOP2A, TGFB1
20	protein heterodimerization activity	GO:046982	8.1	ENO2, ERBB3, ERBB2, TP53, RXRA, PDGFA
21	protein binding	GO:005515	3.5	CAV1, CTNNB1, NTRK1, PPARG, NRG1, SMAD2